BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30
• 31

• Press Releases

  Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral Solution

  May 29, 2025

   · 

  15 min read
• Press Releases

  Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025

  May 29, 2025

   · 

  2 min read
• Press Releases

  InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor Mesutoclax for Myelodysplastic Syndromes in China

  May 29, 2025

   · 

  3 min read
• Press Releases

  Innovent Announces a Phase 3 Study of Picankibart (Anti-IL-23p19 Antibody) Completes First Participant Dosing, Exploring Biologics Switching Treatment for Psoriasis Patients with Prior Inadequate Response to Anti-IL-17 Antibodies

  May 29, 2025

   · 

  10 min read
• Press Releases

  Stealth BioTherapeutics Announces “Path Forward” Despite Disappointing Delay for Ultra-rare Barth Syndrome

  May 29, 2025

   · 

  5 min read
• Press Releases

  Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology

  May 29, 2025

   · 

  4 min read
• Press Releases

  Waters Introduces BioResolve Protein A Affinity Columns to Accelerate Antibody Titer Measurement, Enhancing Process Agility and Batch Quality

  May 29, 2025

   · 

  4 min read
• Press Releases

  Supernus to Participate in the 2025 Jefferies Global Healthcare Conference

  May 29, 2025

   · 

  4 min read
• Press Releases

  Sana Biotechnology to Present at June 2025 Investor Conferences

  May 29, 2025

   · 

  3 min read
• Press Releases

  ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC

  May 29, 2025

   · 

  10 min read